Glaucoma: Sustained-release Drug Delivery System, Topical Agents, and Emerging 3D Visualization Technologies
Complimentary
Released on 3/1/23
Expires on 3/1/24
Program Description
Glaucoma is a heterogeneous group of diseases that has become a significant cause of irreversible blindness worldwide. A glaucoma group of optic neuropathies is characterized by progressive degeneration of retinal ganglion cells. These are central nervous system neurons with cell bodies in the inner retina and axons in the optic nerve. Degeneration of these nerves results in cupping, a characteristic optic disc appearance, and visual loss. The biological basis of glaucoma is poorly understood, and the factors contributing to its progression have not been fully characterized.
Intended Audience
This webcast is designed to meet the educational needs of ophthalmologists, optometrists, retina specialists, advanced practice providers, and nurses caring for a patient with glaucoma.
Commercial Supporter
This activity is supported by an educational grant from Alcon Vision, LLC.
Educational Objectives
Upon completion of the educational activity, participants should be able to:
- Summarize the pathophysiology of glaucoma development
- Assess clinical trial data on new sustained-release drug delivery systems and topical agents in the management of glaucoma
- Appraise the utility of 3D visualization in glaucoma surgery
Accredited Providers
This activity is provided by Amedco, a CME/CE company, and MedNet.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physicians (ACCME) Credit Designation
Designation Statement
Amedco LLC designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses (ANCC) Credit Designation
Designation Statement
Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hour.
Additional Credit Information
Note to Physician Assistants
PAs may claim a maximum of 1.00 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society
Note to Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allows reciprocity for AANPCP continuing education credit for a maximum of 1.00 hour.
Conflicts of Interest Policy
It is the policy of the Amedco to ensure activity content is balanced, independent, objective and based on scientific best-evidence. All persons in a position to control content (i.e., course director, planning committee member and speaker) were required to disclose any relevant financial relationship with a commercial entity relative to the content of his/her presentation.
Every person in a position to control content reported he/she does not have any relevant financial relationships with industry (relative to the content of his/her presentation) to disclose.
Planners’ and Managers’ Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME webcast:
Kamatham A. Naidu, PhD (MedNet) has no relevant financial relationships.
Brian Waggoner (MedNet) has no relevant financial relationships to disclose.
Sheryl Morgan (Amedco) has no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
It is the policy of the Amedco to inform each speaker of his/her responsibility to disclose to the attendees when products or procedures discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved) and of any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.
Each speaker reported he/she will notify the audience if/when discussion includes off-label, unlabeled, experimental, and/or investigational (not FDA approved) information or limited use references within the content of his/her presentation.
Disclaimer
The information provided at this educational initiative is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Non-Endorsement of Products
Amedco do not imply either real or implied endorsement of any product, service, or company referred to in this educational activity.
Faculty
Robert Chang, MD
Associate Professor of Ophthalmology
Stanford University
Palo Alto, CA
Dr. Chang discloses the following:
Research support: Alcon and Genentech
Consultant: Alcon, Genentech, 1800 Contacts, Verana Heath, Sight Sciences, Ocular Therapeutix, Apple, and Belken
Advisor: Smartlens and XP Health
SPV: Iantrek
Felipe A Medeiros, MD, PhD
Joseph AC Wadsworth Distinguished Professor of Ophthalmology
Professor of Electrical and Computer Engineering, and Biostatistics
Duke University, Durham, NC
Dr. Medeiros discloses the following:
Research support: National Eye Institute R01 EY029885, R43 EY027651, Carl-Zeiss Meditec, Inc., Heidelberg Engineering, GmBH, Reichert, and Google, Inc.
Consultant: Allergan, Inc., Novartis, Inc., Reichert; , Carl-Zeiss, Inc., Galimedix, Biogen, Stealth Therapeutics, Annexon
Instructions
There are no fees for participating and receiving CME/CE credit for this webcast. During the period from March 1, 2023, through March 1, 2024, participants must read all the material and study the educational webcast.
This webcast includes text, graphics, and may include multimedia features.
In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 75% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Dashboard or Transcript, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please contact the CME/CE Provider at certificate@amedcoemail.com.
Privacy Policy
Amedco observes privacy and confidentiality of CME/CE information and personal information of CME/CE participants. Third parties receive only aggregated data about CME/CE activities that are relevant to their interests and/or the activities they support.
Webcast
Time to Complete: 1 hour
Released: March 1, 2023
Expires: March 1, 2024
Maximum Credits:
1.00 / AMA PRA Category 1 CreditTM
1.00 / ANCC Contact Hour
Related products
-

Dry Eye Disease: Current and Emerging Novel Tear Stimulating Therapies for Improved Outcomes
Read more -

Emerging Strategies in the Diagnosis and Treatment of Amyotrophic Lateral Sclerosis
Read more -

New Paradigms in the Biological Therapies for Atopic Dermatitis
Read more -

Advances in Blood-based Biomarkers and Disease-Modifying Anti-Amyloid Antibody Therapies for Early-Stage Alzheimer’s Disease
Read more




